| Literature DB >> 28846070 |
Christella E Widjaja1, Jocelyn G Olvera1, Patrick J Metz1, Anthony T Phan2, Jeffrey N Savas3, Gerjan de Bruin4, Yves Leestemaker5,6, Celia R Berkers7, Annemieke de Jong5, Bogdan I Florea4, Kathleen Fisch8, Justine Lopez1, Stephanie H Kim1, Daniel A Garcia1, Stephen Searles9, Jack D Bui9, Aaron N Chang8, John R Yates3, Ananda W Goldrath2, Hermen S Overkleeft4, Huib Ovaa5,6, John T Chang1.
Abstract
During an immune response, CD8+ T lymphocytes can undergo asymmetric division, giving rise to daughter cells that exhibit distinct tendencies to adopt terminal effector and memory cell fates. Here we show that "pre-effector" and "pre-memory" cells resulting from the first CD8+ T cell division in vivo exhibited low and high rates of endogenous proteasome activity, respectively. Pharmacologic reduction of proteasome activity in CD8+ T cells early during differentiation resulted in acquisition of terminal effector cell characteristics, whereas enhancement of proteasome activity conferred attributes of memory lymphocytes. Transcriptomic and proteomic analyses revealed that modulating proteasome activity in CD8+ T cells affected cellular metabolism. These metabolic changes were mediated, in part, through differential expression of Myc, a transcription factor that controls glycolysis and metabolic reprogramming. Taken together, these results demonstrate that proteasome activity is an important regulator of CD8+ T cell fate and raise the possibility that increasing proteasome activity may be a useful therapeutic strategy to enhance the generation of memory lymphocytes.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28846070 PMCID: PMC5617668 DOI: 10.1172/JCI90895
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808